A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

2期进行中（已停止招募） NCT04661150

适应症	Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
分期	2期
申办方	Hoffmann-La Roche
状态	进行中（已停止招募）
受试者人数	42 人
干预（药物）	Atezolizumab, Trastuzumab, Capecitabine, Oxaliplatin
开始日期	2021年3月12日
完成日期	2023年5月8日
结果公布日	2024年10月17日

摘要

This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.

Pathological Complete Regression (pCR) Rate

Completion of neoadjuvant systemic therapy (up to approximately 16 months) · Percentage of Participants

Arm A: Atezolizumab Plus Trastuzumab With XELOX (Capecitabine + Oxaliplatin)	38.1 Percentage of Participants
Arm B: Trastuzumab With XELOX (Capecitabine + Oxaliplatin)	14.3 Percentage of Participants

p-value	0.079
Treatment difference	23.8 (95% CI 1.3–44.7)

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Ad — Hoffmann-La Roche
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patient — National Cancer Institute (NCI)
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Un — University of Southern California
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresecta — National Cancer Institute (NCI)
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients — National Cancer Institute (NCI)

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский